Benralizumab demonstrated a numerical trend of reducing the AAER, but the upper limit of the 95% CI exceeded one (rate ratio: 0.74 [95% CI 0.54–1.02]).
← all excerpts
Efficacy of Biologics in Patients with Allergic Severe Asthma, Overall and by Blood Eosinophil Count: A Literature Review.
1
—
—